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ABSTRACT

Background The Community-Level Interventions for
Pre-eclampsia (CLIP) trials (NCT01911494) in India,
Pakistan and Mozambique (February 2014–2017) involved
community engagement and task sharing with community
health workers for triage and initial treatment of pregnancy
hypertension. Maternal and perinatal mortality was less
frequent among women who received ≥8 CLIP contacts.
The aim of this analysis was to assess the incremental
costs and cost-effectiveness of the CLIP intervention
Handling editor Edwine Barasa
overall in comparison to standard of care, and by PIERS
►► Additional supplemental
(Pre-eclampsia Integrated Estimate of RiSk) On the Move
material is published online only. (POM) mobile health application visit frequency.
To view, please visit the journal
Methods Included were all women enrolled in the three
online (http://dx.d oi.org/10.
CLIP trials who had delivered with known outcomes by
1136/b mjgh-2020-0 04123).
trial end. According to the number of POM-guided home
contacts received (0, 1–3, 4–7, ≥8), costs were collected
LAM and PvD are joint senior
from annual budgets and spending receipts, with inclusion
authors.
of family opportunity costs in Pakistan. A decision tree
model was built to determine the cost-effectiveness of the
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intervention (vs usual care), based on the primary clinical
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endpoint of years of life lost (YLL) for mothers and infants.
Accepted 21 April 2021
A probabilistic sensitivity analysis was used to assess
uncertainty in the cost and clinical outcomes.
Results The incremental per pregnancy cost of the
intervention was US$12.66 (India), US$11.51 (Pakistan)
and US$13.26 (Mozambique). As implemented, the
intervention was not cost-effective due largely to minimal
differences in YLL between arms. However, among women
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effectiveness was ≥80% (all countries).
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Conclusion The intervention was likely to be cost-
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and India, and ≥4 in Pakistan, supporting WHO guidance on
antenatal contact frequency.
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INTRODUCTION
The hypertensive disorders of pregnancy are
one of the primary global causes of maternal
and fetal mortality1 and morbidity, with pre-
eclampsia specifically resulting in an estimated 76 000 maternal and 500 000 perinatal deaths annually.2 Recently, using data
from the Community-Level Interventions for
Pre-
eclampsia (CLIP) cluster randomised
controlled trials (cRCTs) in India, Pakistan,
Mozambique and Nigeria, we estimated the
incidence of pregnancy hypertension in low
and middle-income countries (LMIC) to be at
least 10%, at least as high as in well-resourced
settings.3
Many of the pregnancy hypertension-related
deaths occur either prior to women arriving
at a health facility or after arriving there too
late to prevent a fatal complication.4 As a
result, there has been interest in mobilising
front-line providers, such community healthcare workers (CHWs) to provide earlier care
and facilitate referral to facility.5 6 However,
it has not been demonstrated that such an
approach was effective or cost-effective.
The CLIP cRCTs in India, Pakistan and
Mozambique leveraged the existing CHW
workforce to identify, implement initial
treatment and triage hypertensive pregnant
women in their communities to facility, as well
as to provide education to communities about
obstetric emergencies and the hypertensive
disorders of pregnancy specifically. There
was no evidence that the CLIP intervention was effective in decreasing a composite
of maternal and perinatal mortality and
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Key questions

between countries or according to the number of CHW-
provided contacts a woman received.

What is already known?
►► Recent reviews have indicated that many community health

worker-led initiatives are cost-effective for maternal, neonatal and
child health outcomes in low and middle-income countries (LMICs).
►► Health economic analyses relating to interventions for the hypertensive disorders of pregnancy have been based primarily on diagnostic and clinical interventions.

What are the new findings?
►► The Community-Level Interventions for Pre-eclampsia (CLIP) trials

are the first to undertake a solely community-level intervention for
pregnancy hypertension.
►► Consistent with the primary trial data which demonstrated no
overall benefit, the CLIP intervention was not cost-effective as
implemented.
►► When women received at least eight home-based visits from community health workers, there was a cost-effective reduction in a
composite of maternal and perinatal mortality and morbidity, driven
primarily by perinatal mortality.
►► Data were broadly consistent across three diverse LMIC settings (in
India, Pakistan and Mozambique), and provide support for the cost-
effectiveness of community health worker-led interventions when
staffing levels can support sufficient coverage of the population and
frequency of contacts.

What do the new findings imply?
►► The CLIP trials were not a cost-effective approach to reducing ad-

verse maternal and perinatal outcomes as implemented, but our
findings of increasing cost-effectiveness with higher frequency of
antenatal contacts support community-level intervention if scalability can be achieved.
►► Our data support a role for community health workers in delivering
the eight antenatal care contacts model advocated by the WHO.

morbidity as implemented by the existing workforce.
Consequently, the intervention was received by fewer
women than anticipated (ie, 7055 (90.0%) in India, 11
399 (56.3%) in Pakistan and 4809 (60.4%) in Mozambique).7–10 An a priori-determined contact frequency
analysis indicated effectiveness in reducing maternal and
perinatal mortality and morbidity among women who
received the intervention per protocol; at least four visits
in Pakistan, and at least eight visits in both India and
Mozambique.7–10 These findings were consistent with the
recent WHO eight antenatal care contacts model.
Health economic analyses in such global health trials
are required, as they often provide policy direction for
resource allocation for improving maternal and newborn
health.11 Assessing cost-effectiveness of CHW-led interventions has been a matter of debate,12 and definitive
determination of whether or not such an approach is a
fiscally viable way of reducing adverse maternal and fetal
outcomes is required.
The aim of this study was to assess the cost-effectiveness
of the CLIP trial intervention in each of India, Pakistan
and Mozambique in comparison to standard of care, and
to determine whether or not cost-effectiveness differed
2

METHODS
This was a planned secondary analysis of the clinical and
cost data collected from the CLIP cRCTs in Karnataka
state, India, Sindh province in Pakistan, and Maputo and
Gaza provinces in Mozambique,13 based on a previously
published protocol14 and reported in line with a Consolidated Health Economic Evaluation Reporting Standards
checklist.15 (See online supplemental appendix 1 for the
Statistical Analysis Plan.)
Study population
The CLIP trials targeted pregnant women (15–49 years
in India and Pakistan, and 12–49 years in Mozambique)
across all intervention and control clusters (12 in each of
India and Mozambique, and 20 in Pakistan). All women
enrolled provided written consent. All were included in
the economic analysis provided they had delivered by trial
end and had data on the primary outcome of a composite
of maternal and perinatal morbidity or mortality.
CLIP intervention
The methods for the CLIP trials are described in detail
elsewhere.8 13 Briefly, each of the cRCTs aimed to reduce
all-cause maternal and perinatal morbidity and mortality
by community-level initial triage and treatment of hypertensive women in their community, and timely transfer
to facility. The intervention combined community
engagement and pregnancy hypertension-focused home
contacts by CHWs (ie, accredited social health activists
and auxiliary nurse midwives (India), female health
workers (Pakistan) and Agentes Polivalentes Elementares (Mozambique)). Community engagement meetings focused on pre-eclampsia awareness and education
around birth preparedness and complication readiness,
and included the pregnant women themselves, as well
as their family members and community stakeholders.
CHW-led home contacts were centred around the use of
the PIERS (Pre-eclampsia Integrated Estimate of RiSk)
On the Move (POM) mobile health application for risk
stratification.16 The POM application helped CHWs to
respond to emergency conditions, take women’s blood
pressures, assess proteinuria (using dipsticks at the first
and any subsequently hypertensive visits) and use pulse
oximetry (in Pakistan and Mozambique). For hypertensive women, the POM application directed CHWs to
administer oral methyldopa, intramuscular magnesium
sulfate, or refer to a comprehensive emergency obstetric
care facility depending on the particular circumstance. In
the control group, women received routine antenatal and
postnatal care. In all sites, postnatal care (as a standard)
is rare, but antenatal care rates are high (76% receive at
least four visits in Karnataka, 54% in Sindh and 51% in
Mozambique). Antenatal care in all three sites typically
takes place at local health or primary health centres on
‘antenatal care days’ and is provided by a mix of care
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123
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providers. In both control and intervention arms, relevant demographic, care-seeking and clinical data were
obtained at enrolment, through to 28 days post partum
(newborn) and 6 weeks (mother), through regular cross-
sectional household surveys (every 3–6 months) and, in
India, with additional facility record review.
Health systems
Each of the three healthcare systems has primary health
centres, local inpatient facilities (combined with primary
health centres in India), referral facilities and major
referral centres. Each of the CLIP sites (Karnataka state
in India, Sindh province in Pakistan, and Maputo and
Gaza provinces in Mozambique) was a mix of rural and
periurban settings and therefore does not represent the
countries as a whole. In each setting, the CHWs have not
been well integrated into any of the three formal health
systems. The CLIP intervention was not a formal health
system intervention.
Costs
Within each country, detailed costs associated with
the intervention were collected from annual budgets,
receipts and the number of intervention-related activities performed. Costs were divided into five main categories: (1) CHW training, (2) health worker incentives
for providing POM visits, (3) drug administration costs
resulting from POM visits, (4) community engagement sessions (not including CHW staff costs), and (5)
supplies; for details, see online supplemental table S2.
Total cost of the intervention is the sum of these five categories. Discounting of costs was unnecessary due to the
relatively short time period of the analysis (of less than
2 years). In the main analyses, we did not account for
potential costs associated with differences in care seeking
(antenatally or postnatally) between intervention and
control, as these measures were broadly similar between
arms.7 9 10 In Pakistan, we included out-of-pocket costs to
women, gathered by pilot-tested focus group discussions,
in a separate analysis (online supplemental table S2). In
India and Mozambique, trial resources and logistics did
not permit these group discussions, and only the above
incremental intervention costs were available. We did
not have data available for control arm costs (beyond
those above for Pakistan) and, therefore, these were not
included in the analyses. We did not account for the cost
of trial surveillance in both arms, as a potential scale-up
of this intervention would not incur these costs. Costs
for each country were converted into US$ rates based
on the average exchange rate during the trial (ie, India:
US$1=INR60, Pakistan: US$1=PKR104.7, Mozambique:
US$1=MZN64.67).
Outcomes
The primary clinical endpoint was mortality for mothers
and infants, including stillbirth and neonatal death. These
rates were translated into years of life lost (YLL) based on
country-specific WHO life expectancies.17 In contrast to
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123

the CLIP primary composite outcome, pregnancy-related
morbidities for mothers and newborns were not included,
as there are no validated years of life disabled or disabilities associated with many of these outcomes in any of
the three countries.18 Cost-effectiveness was summarised
by incremental cost-effectiveness ratios (ICERs), which
are interpreted as the average incremental cost relative
to 1 year of life saved. That is, the cost that a policymaker
would have to pay to extend life by 1 year.
Study perspective
The cost-effectiveness analyses were based on a programmatic perspective, comparing the incremental cost of
implementing the intervention both for the overall intervention as delivered, and for various scenarios of POM-
guided contacts delivered. This comparison assessed the
cost to the health system of implementing the CLIP intervention at various levels but did not account for potential
additional costs to women and their families (ie, patient
costs were not included), other than in a secondary analysis in Pakistan.
Data analyses
The primary economic model used for the base case analysis and probabilistic sensitivity analysis was a decision
tree19 based on the following possible decision points: (1)
arm of the trial; (2) number of POM contacts grouped
into one of 0, 1–3, 4–7, or ≥8 (within intervention arm
branch); (3) whether or not a POM-
guided contact
resulted in a referral to facility or use of either methyldopa
or magnesium sulfate at any POM visit; and (4) outcome
of pregnancy: maternal death, stillbirth, neonatal death
or survival. See online supplemental figure S1 for details.
Within each country, the conditional probability at
each branch was estimated directly from the CLIP trial
surveillance and POM data. SEs for these probabilities
were estimated and adjusted for the clustered structure
of the data, and associated mean costs were estimated
for each branch. Community engagement costs were
assumed to be distributed evenly across the varying POM
contact frequency groups. All other costs (CHW training
and incentives, supplies, drugs) were distributed on a
per contact basis, meaning branches on the tree corresponded to groups with more POM-guided contacts and
associated costs, to appropriately estimate the associated
implementation cost of each frequency (‘scenario’)
of the intervention. In addition, we also computed the
average cost per visit by summing the non-community
engagement-related costs (CHW training, CHW incentives, drug administration and supplies) and dividing by
the total number of visits.
We conducted a standard probabilistic sensitivity analysis20 to determine the uncertainty associated with our
analyses. All analyses were carried out using R V.3.5.3
and RStudio interface. For this, probability and costs
for each branch were simulated using the above parameters. Costs were assumed to have gamma distributions,
outcomes were assumed to have beta distributions and
3
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the probability of each number of POM visits was drawn
from a Dirichlet distribution (online supplemental table
S3). These simulations were run 10 000 times for each
country and the results summarised with 95% credible
intervals (as the 2.5th and 97.5th percentiles of the 10
000 runs) for the YLL, cost and ICERs for each trial arm
as well as at each intervention scenario. Results were also
visualised using a cost-effectiveness plane (with points
in the top, right corner considered to be cost-effective),
and with willingness-
to-
pay curves and thresholds for
each YLL averted (which shows for increasing cost to a
decision-maker the likelihood of the intervention is cost-
effective). Willingness-
to-
pay thresholds based on (1)
one and three times the country-specific gross domestic
product (GDP) per capita in 2016 (India=$1729 and
$5188, Mozambique=$429 and $1287, Pakistan=$1368
and $4105) were used21 22 and (2) low and high-range
estimates for country-
level cost-
effectiveness recently
advocated (India=$115 and $770, Mozambique=$8 and
$294, Pakistan=$87 and $669).23
Patient and public involvement
The design of the CLIP trials was informed by extensive
in-country qualitative work with communities, including
focus groups with women, men and other decision-
makers, and community leaders.24–26 There was an experienced patient representative on the Technical Advisory
Group responsible for ongoing study surveillance (see
the Acknowledgements section). Dissemination activities have been held with the participating communities
in each country, and feedback about the intervention
from women was very positive (eg, ‘you have brought the
hospital to my home’).
RESULTS
Data from 61 988 pregnancies of 69 320 enrolled in CLIP
(89.4%) were included in the CLIP economic analyses:
13 017 (88.1%) from India, 35 791 (90.8%) from Pakistan and 13 810 (91.3%) from Mozambique. The rates
of maternal mortality, stillbirth and neonatal death did
not differ between trial arms in any of the CLIP trials,
but women receiving at least eight POM-guided contacts
in India and Mozambique, and at least four contacts in
Pakistan, had lower rates of each of these outcomes, with
stillbirth (India and Pakistan) and neonatal mortality
(Pakistan) being statistically significant, as previously
reported.7–10 Outcome rates and trial intervention details
can be found in table 1.
Given the varying trial sizes, total implementation costs
varied between countries; however, estimates of intervention
costs per pregnancy were similar: US$13.0 in India, US$11.8
in Pakistan and US$15.7 in Mozambique. Table 2 shows that
the majority of the costs in each country were related to POM-
guided contacts and, therefore, costs were proportionately
higher for women as they received an increasing number of
contacts; the largest costs were for tablets and smartphones,
and for the training of CHWs to deliver the intervention. In
4

addition, costs in Pakistan were related to a much higher
number of community engagement sessions compared with
India and Mozambique. Other costs (eg, supplies) were
similar on a per-pregnancy basis. Costs per POM visit were
US$1.44, US$3.81 and US$2.65 in India, Mozambique and
Pakistan, respectively. A complete detailed breakdown of
costs can be found in online supplemental table S1.
In the base case analyses, the intervention was not
found to be cost-effective in any of the three countries
due to the lack of overall difference in maternal and
perinatal mortality between arms (table 3). Similarly,
in the probabilistic analyses, fewer than 50% of samples
were cost-effective in Mozambique and India, and 66%
were cost-
effective in Pakistan (online supplemental
table S4). However, when disaggregating the intervention based on POM-
guided contact frequency group,
the groups receiving ≥8 contacts (per protocol) showed
cost-
effectiveness in the base case in each country
(ICERs=43.3, 48.7 and 9.1 for each of India, Mozambique
and Pakistan, respectively); in addition, the four to seven
contact group was cost-effective in Pakistan (ICER=17.8).
The cost-effectiveness plane (figure 1) depicts the results
from the probabilistic sensitivity analyses; in each country,
>80% of the probabilistic samples were found to be cost-
effective for the ≥8 contact frequency group.
The cost-effectiveness acceptability curves (figure 2)
show the probability of the intervention (for various
scenarios) being cost-effective as a function of a decision-
maker’s willingness to pay to save 1 YLL (log scale). In
each country, if a decision-maker was willing to pay three
times the GDP per capita (red dashed line), the ≥8 contact
scenario (black solid line) has at least 90% certainty of
cost-effectiveness. In Pakistan, at US$400/YLL, the probability of cost-
effectiveness approaches near certainty
(100%) for both the ≥8 and 4–7 contact scenarios (red
dashed line). Similar findings in each country were
found when the willingness-to-pay threshold was reduced
to one times the GDP per capita and when willingness-
to-pay thresholds were lowered to previously published
country-specific recommendations.
In Pakistan, the secondary analyses focusing on a societal perspective (including out-of-pocket costs to women
and their families) yielded similar results to the primary
analysis, although with slightly higher costs associated
with each intervention contact frequency group, corresponding to slight increases in healthcare utilisation in
the intervention arms. Details are in table 3.
DISCUSSION
Principal findings
This study assessed the cost-effectiveness for YLL, from
the health system perspective, of the CLIP interventions
in India, Pakistan and Mozambique. Using the Medical
Research Council Process Evaluation of Complex Interventions guidance27 we observed that the incomplete
implementation process overall resulted in no significant
statistical difference in outcomes between trial arms, and,
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123
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Table 1 Main trial outcomes and intervention
India

Mozambique

Pakistan

Intervention
n=6908

Control
n=6109

Intervention
n=6941

Control
n=6239

Intervention
n=18 441

Control
n=17 350

 

 

 

 

 

 

Composite maternal 1252 (18.1)
and perinatal
outcome (%)

1157 (18.9)

1246 (18)

1172 (18.8)

5373 (29.1)

4187 (24.1)

Maternal mortality
(%)

7 (0.1)

9 (0.1)

15 (0.2)

7 (0.1)

55 (0.3)

51 (0.3)

Maternal morbidity
(%)

371 (5.4)

325 (5.3)

735 (10.6)

690 (11.1)

2213 (12)

1728 (10.0)

Stillbirth (%)

191 (2.8)

156 (2.6)

196 (2.8)

162 (2.6)

935 (5.1)

951 (5.5)

Neonatal death (%) 179 (2.6%)

136 (2.2)

218 (3.1)

171 (2.7)

1011 (5.5)

962 (5.5)

Neonatal morbidity
(%)

813 (11.8)

790 (12.9)

275 (4.0)

362 (5.8)

2375 (12.9)

1684 (9.7)

Intervention

 

 

 

 

 

 

Community
engagement
sessions

1379 groups

–

4243 groups

1379 groups

1368 groups
16 691 CHW led

–

CHWs trained

148

–

79

–

223

–

POM-guided
contacts (n)

57 562

 

26 145

 

 

54 782

POM-guided
contacts per
pregnancy

8.0 (3.0, 12.0)

–

4.0 (2.0, 6.0)

–

3.0 (2.0, 5.0)

–

 0

770
(11.1%)

–

2796 (40.3%)

–

7905
(42.9%)

–

 1–3

1268 (18.3%)

–

936
(13.5%)

–

2718 (14.7%)

–

 4–7

1363 (19.7%)

–

1818 (26.2%)

–

6008 (32.5%)

–

 ≥8

3507 (50.8%)

–

1391 (20.0%)

–

1810 (9.8%)

–

Pregnancies given
methyldopa (%)

60 (1.0)

–

28 (0.7)

–

93 (0.9)

–

Trial outcomes

 Accepted (%)

51 (85.0)

–

19 (67.9)

–

92 (98.9)

–

Pregnancies given
MgSO4 (%)

67 (1.1)

–

28 (0.7)

–

103 (1.0)

–

 Accepted (%)

47 (70.5)

–

13 (46.4)

–

73 (70.9)

–

Pregnancies
referred to facility
(%)

505 (8.2)

–

263 (6.3)

–

487 (4.6)

–

 Accepted (%)

401 (86.7)

–

158 (68.4)

–

305 (83.6)

–

CHW, community healthcare worker; MgSO4, magnesium sulfate; POM, PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the
Move.

therefore, a lack of cost-effectiveness. This was despite
contextual adaptations of the generic protocol to create
bespoke interventions for each country. However, once
fidelity with the published protocol and implementation
plan were achieved in terms of both dose and reach,
maternal and perinatal mortality was significantly lower in
women who received at least eight POM-guided contacts
(four in Pakistan), and that in those scenarios the intervention had a high probability of cost-effectiveness in
each country. The cost of the intervention was remarkably
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123

similar between the three countries on a per-pregnancy
basis (≈US$12–16). In addition, in Pakistan, although
incremental costs were roughly twice as large, there were
similar findings of cost-
effectiveness when including
women’s families’ opportunity (out-of-pocket) costs for
health system resource utilisation.
Interpretation
Several recent reviews have summarised the current
evidence on CHW-led initiatives,28–30 and many previous
5
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Table 2 Summary costs for intervention by country
India

Mozambique

Pakistan

Training of CHWs
Incentives for delivering POM contacts

12 755
39 043

53 205
3097

79 398*

Methyldopa and MgSO4

1365

7163

4864

Community engagement

7048

9201

71 942

Supplies

29 811

45 383

60 949

Total

90 022

108 848

217 153

Total per pregnancy overall

13.0

15.7

11.8

 0 POM-guided contact

1.01

1.35

3.91

 1–3 POM-guided contacts

3.51

9.66

9.56

 4–7 POM-guided contacts

8.06

22.10

17.48

 ≥8 POM-guided contacts
Cost of each POM visit†

18.61
1.44

39.45
3.81

25.78
2.65

All costs in US$.
*Unable to be disaggregated from available data.
†Sum of non-community engagements divided by total number of visits.
CHW, community healthcare worker; POM, PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the Move.

studies have identified cost-
effectiveness for a variety
of CHW-
led interventions in reproductive, maternal,
neonatal and child health,28 29 with further evidence
supporting the use of integrated ‘packages’ of interventions.31 Despite this substantial body of information, many maternal health studies still do not include
a health economic component,14 and those focused on
pre-eclampsia are based on diagnostic and clinical interventions, such as the use of magnesium sulfate.32 33 To
our knowledge, this health economic analysis is the first
to evaluate community-level interventions for pregnancy
hypertension.
The observed differences in clinical and cost consequence outcomes are unlikely to be due to behaviour
change as the individual trial analyses did not identify
increases in care seeking in the intervention (vs control)
clusters.7–10 Therefore, our results are broadly consistent
with prior findings, although requiring a frequency of
contacts from CHWs that matches current WHO guidance. Indeed, the consistently observed decrease in
maternal and perinatal mortality, and increase in cost-
effectiveness, with at least eight POM-
guided contacts
provides external validation of the recent WHO recommendations for at least eight antenatal care contacts.34
The contextual moderators that influenced the fidelity
of implementation probably included the numbers of
deployed CHWs, competing demands on CHW time
(eg, ‘immunisation months’), the variable resilience of
the emergency transport system once women at risk were
identified and the timeliness and quality of the clinical
responses as women ascended the referral system.
Although the overall per-pregnancy costs were similar
between countries, there was discrepancy in the cost of
delivering at least eight POM-
guided contacts, which
was largely driven by differences in CHW training and
6

incentive costs per pregnancy. When considering at-scale implementation of interventions such as CLIP
that require a high number of contacts to be effective,
these cost differences would be important to consider,
as CHW salaries and relative affordability differ between
LMICs.35 36 That said, the relatively low cost in each
country supports CHWs carrying out home-based visits
during pregnancy in LMICs where interventions are
urgently needed to reduce the burden of maternal and
perinatal mortality.
The out-
of-
pocket costs to women in Pakistan were
much higher than those based on the incremental cost
of the intervention to the health system, and reveal the
significant burden placed on families in order to seek
appropriate routine and emergency care, obtain transport to facility and be admitted to health facilities for
delivery. These costs reflect productivity losses due to
pregnancy and pregnancy complications. As most families do not have sufficient savings, without societal safety
nets, large pregnancy-related expenditures are a barrier
for upward social mobility.37 Given the underlying differences in healthcare systems, the generalisation of these
secondary societal results to India, Mozambique or other
LMIC settings should be interpreted cautiously.
Strengths
Our study has several strengths. First, we prospectively
collected both cost and outcome data within our clinical
trial.11 Second, we implemented our intervention across
three diverse settings in Africa and South Asia, and with
a large sample size of >60 000 pregnant women overall.
Therefore, we believe that our findings are generalisable
to other LMIC settings. Further, the details of our budget
allow for clear understanding of the cost of scaling any
one or all components of the intervention. In the case of
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123
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1.16 (−0.43,
3.07)

1.87 (0.58
3.34)

4.53
(3.02,
6.42)

5.23
(4.03,
6.68)

2.94
(2.46,
3.45)

1–3 POM-
guided
contacts

4–7 POM-
guided
contacts

≥8 POM-
guided
contacts

–

3.25 (2.65,
3.94)

18.60
43.28 (−359, 2.44 (1.89,
(11.30, 28.2) 426)
3.08)

Intervention 4.34 (3.60,
is
5.16)
dominated.†

Intervention 5.85 (4.69,
is
7.12)
dominated.†

Intervention 3.13 (2.69,
is
3.62)
dominated.†

Intervention 3.67 (2.42,
is
5.65)
dominated.†

–

–

YLL

−0.81 (−1.70,
0.07)

1.09 (0.08,
2.09)

2.60 (1.28,
4.03)

−0.12 (−0.93,
0.64)

0.41 (−1.00,
2.43)

39.45
(26.15,
55.32)

22.10
(14.97,
30.52)

9.66 (4.80,
16.18)

1.35 (0.71,
2.12)

15.7 (1.40,
40.05)

–

–

All intervals are 95% credible intervals based on the probabilistic sensitivity analysis.
All data are per pregnancy, comparisons are to the control arm and all costs are in US$.
*Includes health system utilisation costs from care seeking reported by focus group.
†Indicates that the intervention has no benefit in years of life lost.
ICER, incremental cost-effectiveness ratio; POM, PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the Move; YLL, years of life lost.

−0.43
(−1.07,
0.22)

8.06 (5.57,
11.02)

3.51 (1.84,
5.77)

1.01 (0.49,
1.73)

3.41
(2.52,
4.43)

0 POM-
guided
contact

0.05 (−0.94,
1.10)

–

13.0 (2.29,
23.6)

0.38 (−0.82,
2.28)

3.74
(2.68,
5.60)

–

Incremental Incremental
YLL
cost
ICER

Intervention –

3.36
(2.97,
3.78)

YLL

–

7.63 (7.16,
8.11)

YLL

7.65 (7.04,
8.30)

48.70 (−155, 4.80 (4.15,
323)
5.48)

Intervention 6.65 (6.21,
is
7.11)
dominated.†

Intervention 9.42 (8.46,
is
10.43)
dominated.†

11.25
(−45.6,
45.7)

−2.83 (−3.64,
−1.99)

−0.98 (−1.63,
−0.31)

1.80 (0.72,
2.94)

0.03 (−0.76,
0.82)

−0.33 (−2.39,
1.60)

25.78
(21.49,
30.32)

17.48
(12.72,
22.96)

9.56 (6.21,
13.59)

3.91 (2.77,
5.25)

11.8 (3.70,
23.41)

–

–

7.29 (5.23,
9.26)

–

7.63 (7.16,
8.11)

YLL

9.11 (6.64,
13.20)

17.84 (9.68,
51.0)

4.80 (4.15,
5.48)

6.65 (6.21,
7.11)

Intervention 9.42 (8.46,
is
10.43)
dominated.†

−2.83
(−3.64,
−1.99)

−0.98
(−1.63,
−0.30)

1.80 (0.72,
2.92)

0.03 (−0.77,
0.83)

−0.34
(−2.38,
1.62)

–

177.22 (169.14, 44.87
183.17)
(29.61,
61.28)

167.89 (156.56, 35.54
176.35)
(18.73,
53.70)

150.87
18.51 (0.00,
(131.70,165.68) 40.21)

143.39 (133.67, 11.03 (0.00,
152.53)
28.24)

15.86 (9.65,
25.7)

36.26
(15.10, 114)

Intervention
is
dominated.†

Intervention
is
dominated.†

67.80 (−316,
330)

–

Incremental
cost
ICER

155.75 (138.41, 23.04 (0.41,
174.89)
48.31)

132.33 (116.79,
145.04).

Incremental
YLL
Cost

Pakistan societal perspective*

Intervention 7.65 (7.04,
is
8.30)
dominated.†

12.94
(−188, 144)

–

–

YLL
intervention– Incremental
control
cost
ICER

Pakistan health system perspective

Intervention 7.29 (5.23,
is
9.26)
dominated.†

–

–

YLL
intervention– Incremental
control
cost
ICER

Mozambique health system perspective

Cost and YLL summaries (95% credible interval from probabilistic sensitivity analyses) based on POM contacts received versus control arm

India health system perspective

Overall

Control
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Figure 1 Probabilistic sensitivity analyses of cost-effectiveness by number of POM-guided contacts received. Points in the
north-east quadrant are classified as cost-effective. All data are per 1000 pregnancies. ctrl, control; int, intervention; POM,
PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the Move.

Pakistan, we found similar cost-effectiveness at increased
POM contacts (but not for the overall intervention)
when including data on out-of-pocket costs to women
and their families, and, therefore, providing a broader
societal perspective on the cost-effectiveness.
We were further able to corroborate our main findings
by including data on out-of-pocket costs to women and
their families, and, therefore, providing a broader societal perspective on the cost-effectiveness.
Limitations
The main challenge associated with our economic analyses is that we were unable to use disability-
adjusted
life-years (DALY) that include maternal and perinatal
morbidity as an outcome measure. This is due to a lack
of reliable DALYs for the collected morbidities in each of
India, Pakistan and Mozambique. Given that we consistently observed similar results in maternal morbidity (no
effect overall, decrease with at least eight POM contacts)
effectiveness
to mortality8 it is probable that the cost-
8

results seen here would be similar if this could be
included.
On the other hand, survived neonatal morbidity was
in some cases increased in the ≥8 POM contact group,
suggesting a trade-off between reduced mortality in this
group and increased survivable morbidity in neonates,
which would require further exploration to determine
severity as well as the values of women, healthcare
providers and their communities. Therefore, the inclusion of these data may have reduced the estimates of cost-
effectiveness seen here.
Furthermore, given the scale of the trial and complexities of the health systems, reliable data on the out-of-
pocket costs to women and health system costs associated
with being referred were unavailable in India and Mozambique; this limits our conclusions to that of a health system
perspective, rather than the preferred ‘societal’ approach
in these two countries.38 Further, the lack of feasibility for
collecting of out-of-pocket costs prevented us from doing
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123
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Figure 2 Cost-effectiveness acceptability curves by number of POM-guided contacts received: probability that the
intervention is cost-effective as a function of a decision-maker’s willingness to pay to save 1 year of life lost. The vertical red
line represents country-specific willingness-to-pay thresholds based on 1× and 3× the gross domestic product (GDP) per
capita. The vertical blue lines represent the low and high points of country-specific willingness-to-pay ranges from Woods et
al23 POM, PIERS (Pre-eclampsia Integrated Estimate of RiSk) On the Move; YLL, years of life lost.

an individual patient-level cost-effectiveness analysis. In
Pakistan, estimates of family opportunity cost data were
available from focus groups, and cost-effectiveness results
were broadly similar to the programmatic perspective.
These analyses relied on extrapolating these estimates to
the larger trial population and therefore should be interpreted cautiously.
In addition, we did not adjust costs for differences in
routine antenatal care seeking between arms as these
measures and the associated cost were not available.
Despite this, these measures were broadly similar between
trial arms, and, therefore, we do not anticipate that this
influenced the results.7 9 10 The CLIP trials relied on
leveraging existing CHWs in each of the sites, and therefore we did not measure costs associated with increasing
the number of CHWs, only the training and materials
associated with the CLIP intervention. Therefore, there
Bone JN, et al. BMJ Global Health 2021;6:e004123. doi:10.1136/bmjgh-2020-004123

would therefore be higher costs in settings where CHWs
are understaffed or not employed.
Finally, the decision tree model used could not adjust
for differences between women who received a low and
high number of POM visits that would have an impact
on mortality, which may introduce a bias due to possible
confounding. That being said, in the analyses of the
primary trial data, adjustment for such measured differences did not affect the association between increased
visits and reduced outcomes.7–10
Meaning
Depending on a decision-
maker’s willingness to pay,
having CHWs deliver home-based interventions at WHO-
recommended frequency thresholds is probably a cost-
effective method for reducing maternal and perinatal
mortality. Reaching these contact frequencies for all
women may be challenging without resources beyond
9
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those available in CLIP. The similarity in the cost of CHW
visits and per-pregnancy trial costs overall between countries points to generalisability to other LMICs.

first draft of the manuscript. The analysis plan was conceived by JNB, ARK, CM and
GWJF. All authors read and approved the final version of the manuscript.

Future work
As further emphasis is placed on increasing the number
of antenatal contacts in LMICs, future studies should
continue to assess the cost-
effectiveness of delivering
these contacts, and integrated interventions by CHWs.
Our data suggest that CHW-
based interventions can
be effective and cost-effective if a sufficient number of
workers are available to deliver them at the required
frequency. Future studies should estimate both health
system and societal perspective costs in settings where
families bare the cost of facility-based care. In addition,
there is a need for continued development of ‘years-of-
life-disabled’ metrics for pregnancy-specific morbidities
so that trials can better estimate the economic impact of
their interventions.
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CONCLUSION
While the CLIP intervention as implemented was not
cost-effective at reducing YLL in any of the three countries, when implemented with at least eight POM-guided
contacts per pregnancy, there was both a reduction in
YLL and a high probability of cost-effectiveness in each
of the three CLIP countries. This supports the eight antenatal care contacts model advocated by the WHO.
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